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a b s t r a c t
Elevated ferritin levels may lead to oxidative stress, and are associated with coronary artery
disease (CAD). Sleep disordered breathing (SDB) is frequently present in atherosclerosis
patients, and causes endothelial dysfunction leading to atherosclerotic plaque progression.
Hypoxic conditions, such as SDB, may upregulate ferritin. The aim of this study was to
evaluate ferritin levels in CAD patients and to correlate ferritin levels with parameters
related to CAD progression, including SDB. We studied 27 patients with CAD (defined as
>30% coronary narrowing) and 29 controls. We found that ferritin was increased in CAD
patients, and was positively correlated with the apnea–hypopnea index (AHI), age, C-
reactive protein (CRP), transferrin, hemoglobin, and testosterone levels, and was negatively
correlated with O2 saturation. Nitrites and nitrates, an indirect measure of nitric oxide (
NO)
concentration, were lower in CAD patients, and were negatively correlated with ferritin. The
increase in ferritin may be related to oxidative stress, suggesting a possible pro-atheroscle-
rotic role of increased ferritin in CAD patients with SDB.
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Coronary artery disease (CAD) is characterized by artery
plaque formation, and is considered an oxidative stress-
associated and inflammation-associated disorder (Bradley and
Floras, 2009; Celen and Peker, 2010; Klein et al., 2010). Morbidity
and mortality due to CAD are often associated with sleep
disordered breathing (SDB) (Mooe et al., 1996; Luthje and
Andreas, 2008; Bradley and Floras, 2009). Obstructive sleep
apnea (OSA) is an important form of SDB, a group of disorders
characterized by abnormalities of respiratory pattern during
sleep. OSA is characterized by repetitive upper airway
obstruction, which leads to intermittent hypoxic sleep condi-
tions (Bradley and Floras, 2009). Intermittent hypoxia induces
inflammatory pathways and oxidative stress, causing func-
tional impairment of the vascular endothelium (Bradley and
Floras, 2009). In vivo and in vitro experiments have provided
evidence of free radical formation in hypoxic conditions (Gozal
and Kheirandish-Gozal, 2008).
Ferritin is a globular protein complex comprising 24
subunits. It is an iron depository structure, and is an iron
source for iron-dependent proteins (Sheftel et al., 2012). The
serum ferritin level correlates with total body iron stores (You
and Wang, 2005). The role of ferritin in oxidative stress is
controversial. Ferritin has been considered to be either an
antioxidant or a pro-oxidant protein complex. Ferritin may
reduce Fe2+ to less reactive Fe3+ utilizing oxygen (O2) or
hydrogen peroxide (H2O2) avoiding oxidative stress by the
Fenton reaction (Chepelev and Willmore, 2011). However, iron
can be released from ferritin during oxidative stress. Superox-
ide radical (O2
) mediates the release of Fe2+ from ferritin and
is rapidly oxidized to Fe3+, contributing to free radical
generation (Paul, 2000).
Elevated serum ferritin levels are associated with high CAD
risk (You and Wang, 2005; Ahluwalia et al., 2010; Torti and
Torti, 2002), and patients with elevated serum ferritin present
increased risk of myocardial infarction (Perez-Lopez et al.,
2010). High serum levels of ferritin increase risk for cardiovas-
cular disease in both men and women (Perez-Lopez et al.,
2010). The development of atherosclerosis may be related to
elevated iron stores, which may increase free radical genera-
tion (Perez-Lopez et al., 2010). Moreover, hypoxia-related
inflammation may participate in ferritin regulation (You and
Wang, 2005; Torti and Torti, 2002). Thus, the role of ferritin in
the development of atherosclerosis is unclear and needs to be
investigated.
Decreased nitric oxide (NO) availability is associated with
OSA and CAD (Jelic et al., 2008). NO is a potent vasodilator and
is a product of nitric oxide synthase (NOS). Endothelial NOS
(eNOS) transiently produces (O2
) in hypoxic conditions,
reducing NO availability and increasing oxidative damage(Singh and Jialal, 2006). OSA causes a reduction in NO-
dependent vasodilatation and may have vascular conse-
quences (Gozal and Kheirandish-Gozal, 2008; Khayat et al.,
2009).
CAD may be related to endocrine alterations (Perez-Lopez
et al., 2010). Endogenous and exogenous steroid hormones are
immunomodulatory, and changes in their levels can modify
inflammatory and oxidative stress pathways (Villablanca
et al., 2010). Frequently, androgens are considered pro-
atherogenic, while estrogens are considered to be anti-
atherogenic hormones (Vitale et al., 2010). Men are more
susceptible to atherosclerosis than women; however, the role
of testosterone in vascular impairment is poorly understood
(Vitale et al., 2010).
The aim of this study was to evaluate ferritin levels in CAD
patients, and to correlate ferritin levels with parameters
related to CAD progression, including SDB. In this logical
extension of our previous study (Klein et al., 2010; Hackenhaar
et al., 2012), we postulated that increased ferritin levels are
related to CAD patients with SDB. Moreover, increased ferritin
may be related to oxidative stress and NO decrease in CAD
patients, further implicating ferritin as a participant in the
pathophysiology of CAD.
Materials and methods
Patients and CAD study
The project was approved by ethics committee of the Hospital
de Clínicas de Porto Alegre, and all participants signed an
informed consent form. A cross-sectional study was con-
ducted by screening patients referred for diagnostic or
therapeutic coronary angiography. The exclusion criteria
were: age less than 35 or greater than 65 years; smoking in
the previous 6 months; clinical diagnosis, dietary, or pharma-
cological treatment for diabetes mellitus; angina in the
previous week; use of anxiolytic medication; treatment for
chronic pulmonary disease; use of vitamin supplement; body
mass index (BMI) ≥ 40 kg/m2; any physical, psychological, or
social issue that would interfere with conducting the home
polysomnographic test; and previous coronary intervention
(surgical or percutaneous myocardial revascularization). Hy-
pertension, past history of smoking, and medication use were
not criteria for exclusion, and the prevalence of these
conditions was similar in both groups. All patients were
assessed by coronary angiography using the same equipment
(SIEMENS Axiom, Germany) and projections, with the table
and image intensifier kept at constant height. A 7 in.
magnification was used for all images. Image quantification
was carried out by the same investigator, who was blinded to
clinical and biochemical variables of the patients. Quantitative
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edge detection system (Siemens, Germany). A guiding catheter
was used for calibration. The following variables were
analyzed: minimal lumen diameter (mm); reference vessel
diameter (mm); lesion extension (mm); and degree of stenosis
(%). Patients with luminal narrowing of 30% or higher were
considered to have CAD. Patients without narrowing or
narrowing less than 30% were included in the control group.
Narrowing of 30% is considered a moderate stenosis. A normal
artery, presenting no obstruction, is considered narrowing of
0%. Total artery obstruction is considered narrowing of 100%.
Previous studies have shown the relevance of 30% narrowing
in the study of CAD (Warlow, 1991; Slattery, 1996; Leclerc et al.,
1999) and even 20–25% narrowing, considered light stenosis,
are relevant in CAD studies (Zhao et al., 2012). Narrowing of
30% was used because of the importance of the diagnosis of
atherosclerosis in this stage, whereas the stroke occurrence
and life expectance reduction are significant. However, surgery
procedure is still controversial in patients presenting moder-
ate stenosis stage (Slattery, 1996).
Sleep study
In the polysomnographic study, a level III portable monitor
(SomnoCheck, Weinmann, Germany) was used at home by the
patients. A nasal cannula connected to a pressure transducer
was employed to quantify air flow and snoring. Inspiratory
effort, pulse oximetry, heart rate, and sleep position were also
verified. The polysomnography respiratory analyses were
made by a sleep specialist who was blinded to clinical and
biochemical variables. Apnea was defined as airflow reduction
to 10% or less of the baseline value persisting for 10 s or more;
hypopnea was defined as airflow reduction of 50% or more,
associated with a reduction of 3% or more in oxygen saturation
(de Oliveira et al., 2009). The AHI was defined as apnea/
hypopnea episodes per hour of total sleep time, calculated by
dividing the sum of total apneas and hypopneas by the hours
of recorded polysomnography.
Laboratory measurements
Approximately 20 mL arterial blood was collected from each
patient from femoral artery puncture for catheterization.
Blood was collected in vials containing coagulation inhibitor,
EDTA and citrate. Immediately after collection, the samples
were refrigerated to 0 8C, centrifuged for 10 min at 0 8C,
aliquoted, and stored at 80 8C. Hemolysates were prepared
by lysing red blood cells with 2% ethanol (ratio 1:10) followed
by centrifugation to obtain crude extracts. High-sensitivity C-
reactive protein, total proteins, ferritin, transferrin, hemoglo-
bin, and erythrocytes were quantified in routine clinical
laboratory analysis; additional tests were performed at the
research laboratory.
Steroid hormones and assay
Steroid hormones were quantified in routine clinical laborato-
ry analysis. Total testosterone was quantified by radioimmu-
noassay (Roche Diagnostics), estradiol was quantified by
electrochemiluminescence immunoassay (Modular E-170,Roche), and progesterone was a quantified by chemilumines-
cence immunoassay (Immulite 1000).
GSH assay
GSH is the most abundant intracellular antioxidant, and its
deficient levels in erythrocytes leads to oxidative stress
(Ellison and Richie, 2012). Total glutathione content (the
sum of reduced glutathione (GSH) and oxidized glutathione
(GSSG)) was measured in hemolysates (Kondo and Awada,
2000). Glutathione reductase (GR) was used to reduce GSSG to
2GSH. GSH was detected through its reaction with 5,5-dithiobis
(acid 2-nitrobenzoic) (DTNB), forming the 5-thio nitrobenzoate
chromophore, detected at 412 nm (Monostori et al., 2009). GSH
concentration was obtained through the subtraction of GSSG
from total glutathione content. Briefly, 50 mL of 2 M perchloric
acid and 4 mM EDTA were added to 50 mL hemolysate. After
vortexing and centrifugation, 10 mL of 0.25 N-ethylmaleimide
was added to 90 mL of supernatant (GSSG assay only). After
new vortexing and centrifugation, 77 mL of 2 M KOH was
added, reaching pH 6. Samples were vortexed and centrifuged
to complete preparation. Samples were maintained in ice. A
standard curve was prepared using 5 mM, 10 mM, 25 mM, and
50 mM GSH in 50 mM phosphate buffer, 5 mM EDTA. The
microplate assay was performed adding 174 mL of 50 mM
phosphate buffer, 17 mL of 4 mM NADPH (in 0.5% NaHCO3), 7 mL
of 6 U/mL GR (in 10 mM phosphate buffer) and 35 mL of sample
or standard. Microplates were incubated at 37 8C for 5 min and
18 mL of 4 mg/mL DTNB (in 100 mM phosphate buffer) was
added. Absorbance at 412 nm was obtained after 2 min
incubation at 37 8C.
GST assay
The enzyme glutathione S-transferase (GST) participates in
oxidative stress detoxification through the conjugation of the
thiol glutathione (GSH) to various substrates, and its poly-
morphisms and decreased activity may be related to athero-
sclerosis (Maciel et al., 2009; Turkanoglu et al., 2010). The
glutathione-S-transferase antioxidant assay is based on
formation of S-(2,4-dinitrophenyl)-glutathione by GST enzy-
matic activity through 1-chloro-2,4-dinitrobenzene (CDNB)
and GSH conjugation (Tsuchida, 2000). Briefly, hemolysates
were centrifuged and maintained on ice. A spectrophotometer
cuvette was filled with 500 mL 0.2 mM potassium phosphate
(pH 6.5), 100 mL 10 mM GSH, 300 mL sample, and 100 mL 10 mM
CDNB (in 2 ethanol:3 water, at 37 8C). All assays were
performed in triplicate. Absorbance was determined at
340 nm. The S-(2,4-dinitrophenyl)-glutathione molar extinc-
tion coefficient at 340 nm (e = 9600 M1 cm1) was used to
calculate GsT activity.
Nitrites/nitrates assay
The Griess reaction, which measure nitrites and nitrates in
the sample, was employed to determine circulating NO
concentration (Bryan and Grisham, 2007). Hemolysates were
centrifuged and maintained on ice. A standard curve was
made using 1 mM sodium nitrite (NaNO2) diluted in 100 mM
phosphate buffer to standard curve concentrations of
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the microplate (all wells in triplicate) 100 mL of sample or
standards were add, followed by 50 mL of Griess regent
(0.02 g of naphthylenediamine dichloride, 0.2 g of sulfanil-
amide, 500 mL of orthophosphoric acid and 10 mL of MilliQ
water). The microplate was protected from light during
a10 min incubation. Absorbance was read at 543 nm
(Grisham et al., 1996).
Statistical analysis
Categorical variables are presented as absolute values and
were analyzed by chi-square test. The Kolmogorov–Smirnov
test of normality was employed to verify distribution of
variables. Variables with normal distribution are presented
as mean  standard error (SE); means were compared by
student's t-test. Variables without normal distribution are
presented as median (minimum–maximum); medians were
compared by Mann–Whitney U test. Spearman coefficient
was employed to test correlation between variables
without normal distribution, and Pearson coefficient was
used to test correlation between variables with normal
distribution. Data were analyzed at the significance level





Lowest O2 saturation (%) 
Number of coronaries with >30% stenosis 
Number of coronary segments with >30% stenosis 
Categorical data are presented as n (%). Variables with normal distributio
are presented as median (range).
a Statistically significant as compared with control group. BMI, body mas
hypopnea index (apnea–hypopnea/hour of sleep).
Table 2 – Patient biochemical data.
Contr
CRP (mg/L) 1.5
Erythrocytes (million erythrocytes/mL) 4.4
Hemoglobin (g/dL) 13.0
Ferritin (ng/mL) 144.0
Transferrin (mg/mL) 255 (
Total testosterone (ng/mL) 0.6
Estradiol (pg/mL) 18.1
Progesterone (ng/mL) 0.2
Total glutathione (mmol/g Hb) 438.4
GSH (mmol/g Hb) 329.6
GSSG (mmol/g Hb) 78.6
GsT (U/mL) 0.0
Nitrites/nitrates (nmol/mg Hb) 0.7
Variables with normal distribution are presented as mean  SE. Variable
a Statistically significant as compared with control group. Total glutathio
oxidized glutathione.Results
Clinical and anthropometric data in CAD groups
Table 1 presents anthropometric and clinical data of analyzed
patients. Gender and body mass index (BMI) did not differ
between groups (Table 1). CAD patients were significantly
older than controls (Table 1). AHI was significantly higher in
the CAD group, and lowest O2 saturation was decreased in the
CAD group (Table 1).
Biochemical data in CAD groups
Table 2 presents biochemical data from the analyzed patients.
The inflammatory marker, high-sensitivity C-reactive
protein (CRP), as well as the analyzed steroid hormones
testosterone, estradiol and progesterone were not significantly
different between groups (Table 2). Hematocrit and hemoglo-
bin concentration were significantly increased in CAD
patients, while erythrocytes presented no difference between
groups (Table 2). CAD patients presented significantly in-
creased ferritin levels, however there was no difference in
transferrin or free iron concentrations (Table 2). GsT activity,Control group (n = 29) CAD group (n = 27)
12 (41%) 19 (70%)
51.62  1.28 56.96  1.11a
27.30  0.74 27.79  0.74
7 (1–48) 17 (1–56)a
87.5 (63–93) 85.0 (77–90)a
0 (0–0) 1.95 (0.83)
0 (0–0) 2.3 (1.42)
n are presented as mean  SE. Variables without normal distribution
s index (weight divided by the square of height, kg/m2); AHI, apnea–
ol group (n = 29) CAD group (n = 27)
9 (0.19–21.50) 2.00 (0.16–18.40)
7  0.06 4.65  0.07
4  0.24 13.77  0.25a
0 (8.3–720.3) 302.35 (45.50–685.80)a
183–371) 236 (160–296)
3 (0.11–8.06) 3.55 (0.11–6.93)
0 (5.00–411.60) 25.00 (5.00–624.70)
9 (0.15–6.11) 0.26 (0.15–25.01)
4 (52.63–5564.45) 440.30 (57.85–3854.17)
7 (34.44–5445.85) 403.04 (85.30–3654.09)
2 (8.86–558.50) 86.65 (19.37–880.63)
54  0.004 0.047  0.003
6 (0.39–1.11) 0.57 (0.26–1.22)a
s without normal distribution are presented as median (range).
ne, GSH + GSSG erythrocyte content; GSH, reduced glutathione; GSSG,
Fig. 1 – Ferritin vs. apnea–hypopnea index (AHI). Spearman's correlation analysis of apnea–hypopnea index (AHI) and serum
ferritin concentration. *Statistically significant. Positive rho value: positive correlation between variables.
Fig. 2 – Ferritin vs. lowest O2 saturation (%). Spearman's correlation analysis of lowest O2 saturation (%) and serum ferritin
concentration. *Statistically significant. Negative rho value: negative correlation between variables.
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Fig. 3 – Ferritin vs. C-reactive protein. Spearman's correlation analysis of serum C-reactive protein concentration and serum
ferritin concentration. *Statistically significant. Positive rho value: positive correlation between variables.
Fig. 4 – Ferritin vs. age. Spearman's correlation analysis of age (years) and serum ferritin concentration. *Statistically
significant. Positive rho value: positive correlation between variables.
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Fig. 6 – Ferritin vs. testosterone. Spearman's correlation analysis of serum testosterone concentration and serum ferritin
concentration. *Statistically significant. Positive rho value: positive correlation between variables.
Fig. 5 – Ferritin vs. nitrites/nitrates. Spearman's correlation analysis of erythrocytes nitrites/nitrates concentration and serum
ferritin concentration. *Statistically significant. Negative rho value: negative correlation between variables.
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differ between controls and CAD patients (Table 2). Nitrites
and nitrates were significantly lower in CAD patients than
controls (Table 2).
Correlation analysis
In Spearman's correlation analysis, ferritin correlated with AHI
(rho = 0.394, P = 0.003, Fig. 1), lowest O2 saturation (rho = 0.352,
P = 0.010, Fig. 2), CRP (rho = 0.280, P = 0.042, Fig. 3), age
(rho = 0.407, P = 0.002, Fig. 4), nitrites/nitrates (rho = 0.273,
P = 0.044, Fig. 5), transferrin (rho = 0.279, P = 0.039) and hemo-
globin (rho = 0.500, P = 1.003  104), however no correlation was
found between AHI and CRP (rho = 0.104, P = 0.449) or AHI
and nitrites/nitrates (rho = 0.066, P = 0.624). Spearman's anal-
ysis of total testosterone levels showed correlation with ferritin
(rho = 0.596, P = 2  106, Fig. 6), transferrin (rho = 0.344,
P = 0.010), hemoglobin (rho = 0.579, P = 2.882  106), erythro-
cytes (rho = 0.544, P = 1.446  105) and hematocrit (rho = 0.544,
P = 5.0568  106), however no correlation was found between
testosterone and available iron (rho = 0.233, P = 0.086).
Discussion
CAD patients exhibited increased ferritin, which was positive-
ly correlated with the apnea–hypopnea index (AHI) and was
negatively correlated with O2 saturation and
NO levels. CAD
patients exhibited decreased NO levels. The increase in
ferritin may be related to oxidative stress, suggesting a
possible pro-atherosclerotic role in CAD patients with SDB.
Serum ferritin levels are related to cardiovascular diseases
in both men and women (Berge et al., 1994; Olesnevich et al.,
2012). In male patients, a serum ferritin level of 200 ng/mL is
associated with a 2.2-fold increase in the risk for myocardial
infarction (Olesnevich et al., 2012), which is consistent with
our results showing that the median serum ferritin level in
CAD patients was 302 ng/mL, significantly higher than the
control group (median 144 ng/mL) (Table 2). Ferritin serum
concentration is also related to coronary artery calcium levels
in male patients, an early biomarker of atherosclerosis (Sung
et al., 2012). The majority of CAD researchers consider ferritin
to be an antioxidant, and consequently, anti-atherosclerotic
because of its role in iron sequestration (You and Wang, 2005).
However, our results are consistent with a pro-oxidant and
pro-atherosclerotic role of ferritin. As discussed by Halliwell
and Gutteridge (2007), ferritin is more likely to cause, rather
than ameliorate, oxidative stress (Halliwell and Gutteridge,
2007), possibly by participating in LDL oxidation in atheroscle-
rotic lesions (Ahluwalia et al., 2010). We suggest ferritin
participates in CAD progression, contributing to oxidative
stress. Hypoxic conditions, such as SDB, produce superoxide
radical through changes in the activity of endothelial NOS
(eNOS) (Singh and Jialal, 2006) and xanthine dehydrogenase
(XDH) (Cuzzocrea et al., 2001). Since iron is released from
ferritin by superoxide radical (O2
) (Paul, 2000), we suggest
this may be a pro-oxidant mechanism responsible for the
participation of ferritin in the progression of atherosclerosis.
Moreover, the release of iron by superoxide radical occurs to
ferritin-bound iron but not to transferrin-bound iron(Paul, 2000). These finding are consistent with our results,
where increased ferritin levels are related to CAD (Table 2) and
SDB (Figs. 1 and 2) and not to transferrin (Table 2).
The pro-atherosclerotic role of ferritin is reaffirmed by the
significant, albeit relatively weak, positive correlation found
between serum ferritin levels and the inflammatory biomarker
CRP (Fig. 2). Moreover, ferritin correlated negatively with NO
levels (Fig. 5). CRP, which is an acute phase protein usually
expressed in the liver during inflammation, is expressed in
smooth muscle cells from atherosclerotic arteries (Kampoli
et al., 2012). The majority of patients (including controls) in this
study presented higher CRP levels compared to clinical
reference levels. Consequently, no relationship between CRP
levels and CAD (Table 2) or AHI (data not shown) was found. A
related CAD study did not identify an association between
ferritin levels and CRP (Grisham et al., 1996).
We observed a positive correlation between ferritin levels
and AHI (Fig. 1), and a negative correlation between ferritin
levels and lowest O2 saturation (Fig. 2), which corroborated a
previous report of ferritin upregulation by hypoxia (Torti and
Torti, 2002). Moreover, the positive correlation with AHI
suggests that ferritin levels are related to SDB in CAD patients.
Exogenous testosterone increases erythropoiesis and hemo-
globin levels; however, associated differences in transferrin
receptor, erythropoietin, or ferritin levels have not generally
been reported (Coviello et al., 2008; Rushton and Barth, 2010). In
our study, testosterone levels were positively correlated with
ferritin levels (Fig. 6), erythrocytes numbers, and hemoglobin
levels, and were negatively correlated with transferrin levels
(see section ‘‘Correlation analysis’’). However, no significant
correlation was found between testosterone and available iron
(see section ‘‘Correlation analysis’’). It is important to highlight
that healthy men present higher baseline levels of ferritin
compared to women (Perez-Lopez et al., 2010), and this may be
the main cause of the correlation found between testosterone
and ferritin, as well as the correlation with erythrocyte numbers
and hemoglobin concentration. Ferritin serum levels are
upregulated by heme (Chepelev and Willmore, 2011), and there
is a well known relationship of ferritin with hemoglobin and
hematocrit (Chepelev and Willmore, 2011; Sheftel et al., 2012), as
was observed in our patients (see section ‘‘Correlation analysis’’).
Our findings (shown in Fig. 4) are consistent with the well-
known relationship between ferritin levels and age (Berge
et al., 1994).
NO inhibits plaque formation, arterial constriction, plate-
let aggregation, and macrophage adhesion and penetration
(Vanhoutte, 2009). Reduced NO availability is associated with
CAD and SDB (Jelic et al., 2008). The level of nitrites and
nitrates, an indirect measure of NO, was significantly lower in
our CAD patients (Table 2), indicating that NO decrease may
be related to atherosclerosis progression. Oxidative stress
generated by hypoxia in SDB alters NO-dependent vasodila-
tation (Atanasiu et al., 2007). In this regard, our patients
exhibited a negative correlation between NO and ferritin
(Fig. 5). However, nitrite and nitrate levels did not correlate
with AHI in our study (see section ‘‘Correlation analysis’’). Thus,
further work will be necessary to clarify the role of ferritin in
CAD progression.
There are important limitations regarding the patients
included in this study. The control group in this study
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narrowing. The included patients and controls were all
referred for diagnostic or therapeutic coronary angiography
by a physician prior to participation in the study. All patients
presented CRP levels that were higher than clinical reference
levels for healthy people. The selection of controls was driven,
in part, by the fact that healthy patients are not referred for
coronary angiography, which is considered a moderate risk
procedure. Another limitation was the absence of SDB groups,
since AHI was measured as a continuous variable in all
patients. Despite the fact that AHI was significantly lower in
the control CAD group, not all controls were SDB free.
Conclusions
The findings reported here provide evidence of the relevance
of increased ferritin levels in CAD patients with SDB. Ferritin
may cause oxidative stress in CAD patients, thereby partici-
pating in progression of atherosclerosis. NO decrease is
correlated with ferritin levels and may be related to athero-
sclerosis progression in CAD patients with SDB.
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